Jane Huang - Jan 4, 2024 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
President, CMO
Signature
/s/ Laurent Chardonnet, Attorney-in-Fact
Stock symbol
PRLD
Transactions as of
Jan 4, 2024
Transactions value $
-$14,492
Form type
4
Date filed
1/8/2024, 05:00 PM
Previous filing
Oct 6, 2023
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRLD Common Stock Options Exercise +9.38K +23.6% 49.1K Jan 4, 2024 Direct F1
transaction PRLD Common Stock Tax liability -$14.5K -3.84K -7.83% $3.77 45.3K Jan 4, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Restricted Stock Unit Options Exercise $0 -9.38K -10% $0.00 84.4K Jan 4, 2024 Common Stock 9.38K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
F2 Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.
F3 The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.